Pod Engine
Podcast thumbnail for Oncology Medical Conversation Video

Oncology Medical Conversation Video

Claim This Podcast

by COR2ED Medical Education

5.0(1 reviews)
35 episodes
Updated Bi-weekly
Accepts GuestsHas SponsorsLocation 🇬🇧
27

Podcast Authority

Beta
PoorBased on show quality, social media presence, reviews, charts, and more
Pod Engine
Quality43
Social0
YouTube0
Engagement27
Learn more

Podcast Overview

Join oncology experts as they discuss their approaches to diagnosing and managing patients with gastrointestinal, genitourinary, lung, breast, gynecological, neuroendocrine and hematological cancers, sarcomas, and more. The conversations also explore cutting edge developments in precision oncology, as well as emerging treatments, including immunotherapy. This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit www.cor2ed.com

Language

🇺🇲

Publishing Since

12/6/2023

Visit WebsiteAppleView on Apple PodcastsRSS Feed

Unlock The Full Podcast Authority Score Report

See how your podcast performs across key metrics

27

Podcast Authority

Beta
PoorBased on show quality, social media presence, reviews, charts, and more
Pod Engine
Quality43
Social0
YouTube0
Engagement27
Learn more
6
Excellent Areas
2
Good Performance
11
Growth Opportunities
excellent
Episode Length
20 minutes
Performing excellently!
good
Show Experience
31 episodes over 1.4 years

Recommendations available

Unlock the full report to see detailed tips

needs improvement
Publishing Consistency
Every 17 days

Recommendations available

Unlock the full report to see detailed tips

+16 More Metrics

Unlock comprehensive insights including:

  • • YouTube presence analysis
  • • Social media reach metrics
  • • RSS compliance scoring
  • • Podcast 2.0 features
  • • Technical standards
What's Included in Your Full Report

Detailed Analytics

  • Complete breakdown of all 19 authority metrics
  • Personalized recommendations for each metric
  • Industry benchmarks and comparisons
  • Technical RSS feed analysis and compliance scoring

Growth Strategies

  • Step-by-step action plans for improvement
  • Quick wins to boost your score immediately
  • Pro tips from successful podcasters
Get your free podcast insights report

See how your show performs across every key metric

Instant delivery
No spam
Attract Better Guests

High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.

Secure Sponsorships

Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.

Grow Your Audience

Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.

1 verified contact email on file for Oncology Medical Conversation Video

Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.

See contact details

Recent Episodes

Episode thumbnail for Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

March 12, 2026

Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Pre-analytical Phase Challenges and Biomarker Testing in HER2+ Metastatic Breast Cancer    Key clinical takeaways:   Metastatic breast cancer (mBC) is a complex, heterogeneous disease requiring multidisciplinary collaboration. Pathologists are central to this process to ensure accurate interpretation and optimal patient management    Incorporating HER2-low and HER2-ultralow categories in biomarker testing is critical for mBC due to the demonstrated efficacy of HER2-targeted antibody-drug conjugates, such as trastuzumab deruxtecan, in these patient subsets, expanding therapeutic options beyond traditional HER2-positive cases    High-quality pre-analytical handling and nuanced interpretation are essential for accurate HER2 classification, particularly for HER2-low and –ultralow disease. Small errors in testing or interpretation can lead to missed treatment opportunities.      This is the full video. Watch the shorter highlights video here: https://cor2ed.com/precision-oncology-connect/programmes/biomarker-testing-breast-cancer/?media=0    Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying one-page snapshot: https://cor2ed.com/precision-oncology-connect/programmes/biomarker-testing-breast-cancer/?media=2     Follow us on social media:  LinkedIn: https://linkedin.com/company/ntrk-connect  X: https://x.com/PresOnc_Connect    This content is intended for healthcare professionals only.   This video is supported by an Independent Education Grant from Daiichi Sankyo.    This video is developed by cor2ed.com  Published on March 2026.    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Episode thumbnail for Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

December 17, 2025

Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification

Understanding HER2-low and HER2-ultralow classification in mBC In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binary HER2 model translates into everyday clinical practice. The experts explore: Key efficacy data from DESTINY-Breast04 and DESTINY-Breast06, and their impact on the HER2 treatment framework The clinical relevance of HER2-low and HER2-ultralow categories, and review the CAP reporting template When and why to perform re-biopsy to detect changes in HER2 expression over time Best practices for monitoring and managing T-DXd–related adverse events, including nausea, vomiting, fatigue and ILD/pneumonitis   Watch now to deepen your understanding of HER2-low and HER2-ultralow classification, refine how and when you test, and appreciate the impact on therapeutic decision-making in mBC.   Clinical takeaways   DESTINY-Breast04 and DESTINY-Breast-06 established T-DXd as an effective option for HER2-low and HER2-ultralow mBC, improving PFS and OS and showing that even minimal HER2 expression can identify patients who benefit from T-DXd Current CAP reporting template separates HER2-low (IHC 1+ or 2+/ISH–) and HER2-ultralow (IHC 0 with faint or incomplete membrane staining in ≤10% of tumour cells) from true HER2-0, creating treatment-defining strata for HER2-targeted ADCs such as T-DXd Because HER2 expression is dynamic between primary and metastatic sites and over time, re-biopsy at progression, particularly in tumours previously scored as HER2-0, should be considered to identify new candidates for T-DXd T-DXd delivers substantial antitumour activity, but treatment-related adverse events, including nausea, vomiting, fatigue, alopecia and, in particular, ILD/pneumonitis, require careful and proactive management. Clinicians should apply structured supportive care and early, vigilant monitoring to ensure safe and sustained treatment       This is the full video. Watch the shorter highlights video here: https://youtu.be/3xepcF70Ljw   Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website   Follow us on social media: LinkedIn: https://www.linkedin.com/company/breastcancerconnect/ X: https://x.com/BreastCaConnect   This content is intended for healthcare professionals only.   This programme is supported by an Independent Education Grant from AstraZeneca. This podcast is developed by cor2ed.com   Published December 2025   Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Episode thumbnail for Understanding EP-NEC: Through Diagnosis, Treatment, and Support

November 7, 2025

Understanding EP-NEC: Through Diagnosis, Treatment, and Support

In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressive, and often misunderstood subset of neuroendocrine cancers.   They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches, including DLL3-targeted therapies.   Through both HCP and patient-centred perspectives, the conversation addresses real-world challenges, the importance of support networks, and the growing sense of hope for people affected by this difficult disease.  Key clinical takeaways:   Unlike NETs, EP-NECs are poorly-differentiated, high-grade, aggressive, and fast-growing cancers with, currently, a poor prognosis  While there remains a medical need for effective treatment of EP-NECs, clinical studies with DLL3-targeted agents show promise  Accessing a support network can provide emotional reinforcement and information for patients and their care partners    You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/net-connect/programmes/ep-nec-diagnosis-treatment-support/?media=0  Or watch on YouTube: https://youtu.be/nfng2s3jSw8  Follow us on social media:  LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true   X: https://x.com/net_connectinfo/status/1837039277353382012   This podcast is supported by an Independent Education Grant from ITM.   This podcast is developed by cor2ed.com  Published in November 2025    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

35 total episodes available

Deep-dive analytics for Oncology Medical Conversation Video

Sign up to explore

Frequently asked questions

Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.

What is Oncology Medical Conversation Video?

Join oncology experts as they discuss their approaches to diagnosing and managing patients with gastrointestinal, genitourinary, lung, breast, gynecological, neuroendocrine and hematological cancers, sarcomas, and more. The conversations also explore cutting edge developments in precision oncology, as well as emerging treatments, including immunotherapy.

This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit www.cor2ed.com

How often does this podcast release new episodes?

This podcast updates bi-weekly.

Where can I listen to this podcast?

This podcast is available on 6 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.

Does this podcast accept guests?

No, this podcast does not typically feature guests.

Legal Disclaimer

Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.

All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.

We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.

While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.

By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.